Abstract

BackgroundRheumatoid Arthritis (RA) patients with high body mass index (BMI) have been known to respond less well to anti-tumor necrosis factors (TNFs), especially infliximab. The post-hoc analysis of PLANETRA [1],...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call